Answers are grounded in this paper and cite their sources.
Evaluates antifungal effectiveness of novel 1,3,4-oxadiazole agents against Candida albicans biofilms, suggesting potential therapeutic benefits.
The increasing prevalence of drug-resistant Candida albicans, particularly in biofilm-associated infections, highlights the urgent need for structurally novel antifungal agents. The objective of this study was to design, synthesize, and evaluate 7-azaindole–incorporated 1,3,4-oxadiazole hybrids 5(a–n) as potential antifungal and antibiofilm agents. The novelty of this work lies in integrating 7-azaindole and 1,3,4-oxadiazole pharmacophores into a single hybrid framework and evaluating their biological, structural, and computational properties. The target compounds were synthesized via a three-step protocol in yields of 80–94% and characterized using LC–MS, FT-IR,1H NMR, and 1³C NMR spectroscopy, while SCXRD analysis was performed for lead compound 5j. Antifungal evaluation against C. albicans revealed MIC values of 8–64 µg/mL. Compound 5j exhibited activity comparable to fluconazole, with MIC and MFC values of 8 and 32 µg/mL, respectively. It inhibited biofilm formation by 71.56 ± 1.28% and filamentation by 64.18 ± 1.21%. qRT–PCR analysis showed downregulation of HWP1 and ALS3 to 0.35 ± 0.02- and 0.39 ± 0.02-fold, respectively. Molecular docking suggested favorable predicted interactions of 5j with ALS3, with a Glide score of −7.89, while DFT calculations showed a HOMO–LUMO energy gap of ΔEg = 4.875 eV. Overall, compound 5j represents a promising lead against C. albicans biofilm-associated infections.
No takes yet. Share an insight, caveat, or question.
Nagaraju et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: